par De la Fuente, José Manuel;Lotstra, Françoise 
Référence European neuropsychopharmacology, 4, 4, page (479-486)
Publication Publié, 1994-12

Référence European neuropsychopharmacology, 4, 4, page (479-486)
Publication Publié, 1994-12
Article révisé par les pairs
Résumé : | Borderline personality disorder does not have a first choice pharmacological treatment. We studied 20 borderline inpatients in a double-blind parallel placebo-controlled trial with carbamazepine for a mean of 30.9 days. No significant positive effects of the drug were found. |